AbbVie (ABBV) Retained Earnings (2012 - 2026)
AbbVie (ABBV) posted quarterly Retained Earnings of -$17.9 billion for Q1 2026, down 87.59% year-over-year from -$144.0 billion in Q1 2025, and down 15.36% quarter-over-quarter from -$15.5 billion in Q4 2025.
AbbVie (ABBV) Retained Earnings (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Retained Earnings for 15 consecutive years, with -$17.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 87.59% year-over-year to -$17.9 billion; the TTM figure through Mar 2026 stood at -$17.9 billion (down 87.59% YoY), while the FY2025 annual figure was -$15.5 billion, down 96.11% from the prior year.
- Retained Earnings declined to -$17.9 billion in Q1 2026 per ABBV's latest filing, from -$15.5 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $3.5 billion in Q2 2022 and bottomed at -$17.9 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$5.4 billion across 5 years, with a median of -$3.0 billion in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 213.31% — and 2025, when it tumbled 299.62%.
- AbbVie's Retained Earnings stood at -$2.2 billion in 2022, then dropped by 4.82% to -$2.3 billion in 2023, then sank by 242.73% to -$7.9 billion in 2024, then plunged by 96.11% to -$15.5 billion in 2025, then fell by 15.36% to -$17.9 billion in 2026.
- Business Quant data shows ABBV's Retained Earnings at -$17.9 billion in Q1 2026, -$15.5 billion in Q4 2025, and -$14.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.33 Bn | 630.58 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.67 Bn | 463.10 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 374.13 Bn | 366.99 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 302.76 Bn | 295.07 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.15 Bn | 252.25 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 182.54 Bn | 179.36 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 105.99 Bn | 101.83 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.33 Bn |
| Mar 31, 2026 | -17.87 Bn |
| Dec 31, 2025 | -15.49 Bn |
| Sep 30, 2025 | -14.23 Bn |
| Jun 30, 2025 | -1.54 Bn |
| Mar 31, 2025 | -9.53 Bn |
| Dec 31, 2024 | -7.90 Bn |
| Sep 30, 2024 | -4.96 Bn |
| Jun 30, 2024 | -3.77 Bn |
| Mar 31, 2024 | -2.38 Bn |
| Dec 31, 2023 | -2.31 Bn |
| Sep 30, 2023 | -2.35 Bn |
| Jun 30, 2023 | -2.25 Bn |
| Mar 31, 2023 | -2.23 Bn |
| Dec 31, 2022 | -2.20 Bn |
| Sep 30, 2022 | -3.44 Bn |
| Jun 30, 2022 | 3.52 Bn |
| Mar 31, 2022 | -2.98 Bn |
| Dec 31, 2021 | 3.13 Bn |
| Sep 30, 2021 | -3.16 Bn |